Prognostic Utility of Cardiovascular Magnetic Resonance-Based Phenotyping in Patients With Muscular Dystrophy.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
07 11 2023
Historique:
medline: 8 11 2023
pubmed: 6 11 2023
entrez: 6 11 2023
Statut: ppublish

Résumé

Background The prognostic utility of cardiovascular magnetic resonance imaging, including strain analysis and tissue characterization, has not been comprehensively investigated in adult patients with muscular dystrophy. Methods and Results We prospectively enrolled 148 patients with dystrophinopathies (including heterozygotes), limb-girdle muscular dystrophy, and type 1 myotonic dystrophy (median age, 36.0 [interquartile range, 23.0-50.0] years; 51 [34.5%] women) over 7.7 years in addition to an age- and sex-matched healthy control cohort (n=50). Cardiovascular magnetic resonance markers, including 3-dimensional strain and fibrosis, were assessed for their respective association with major adverse cardiac events. Our results showed that markers of contractile performance were reduced across all muscular dystrophy groups. In particular, the dystrophinopathies cohort experienced reduced left ventricular (LV) ejection fraction and high burden of replacement fibrosis. Patients with type 1 myotonic dystrophy showed a 26.8% relative reduction in LV mass with corresponding reduction in chamber volumes. Eighty-two major adverse cardiac events occurred over a median follow-up of 5.2 years. Although LV ejection fraction was significantly associated with major adverse cardiac events (adjusted hazard ratio [aHR], 3.0 [95% CI, 1.4-6.4]) after adjusting for covariates, peak 3-dimensional strain amplitude demonstrated greater predictive value (minimum principal amplitude: aHR, 5.5 [95% CI, 2.5-11.9]; maximum principal amplitude: aHR, 3.3 [95% CI, 1.6-6.8]; circumferential amplitude: aHR, 3.4 [95% CI, 1.6-7.2]; longitudinal amplitude: aHR, 3.4 [95% CI, 1.7-6.9]; and radial strain amplitude: aHR, 3.0 [95% CI, 1.4-6.1]). Minimum principal strain yielded incremental prognostic value beyond LV ejection fraction for association with major adverse cardiac events (change in

Identifiants

pubmed: 37929714
doi: 10.1161/JAHA.123.030229
doi:

Substances chimiques

Contrast Media 0
Gadolinium AU0V1LM3JT

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e030229

Auteurs

Niharika Kashyap (N)

Division of Cardiology University of Alberta Edmonton Alberta Canada.
Department of Medicine, Faculty of Medicine and Dentistry Mazankowski Alberta Heart Institute, University of Alberta Edmonton Alberta Canada.

Anish Nikhanj (A)

Division of Cardiology University of Alberta Edmonton Alberta Canada.
Department of Medicine, Faculty of Medicine and Dentistry Mazankowski Alberta Heart Institute, University of Alberta Edmonton Alberta Canada.

Dina Labib (D)

Department of Cardiac Sciences University of Alberta Edmonton Alberta Canada.
Libin Cardiovascular Institute of Alberta, University of Calgary Calgary Alberta Canada.

Easter Prosia (E)

Department of Cardiac Sciences University of Alberta Edmonton Alberta Canada.
Libin Cardiovascular Institute of Alberta, University of Calgary Calgary Alberta Canada.

Sandra Rivest (S)

Department of Cardiac Sciences University of Alberta Edmonton Alberta Canada.

Jacqueline Flewitt (J)

Libin Cardiovascular Institute of Alberta, University of Calgary Calgary Alberta Canada.

Gerald Pfeffer (G)

Department of Clinical Neurosciences University of Calgary Calgary Alberta Canada.
Hotchkiss Brain Institute, University of Calgary Calgary Alberta Canada.

Jeffrey A Bakal (JA)

Alberta Strategy for Patient Oriented Research Unit University of Calgary Calgary Alberta Canada.
Provincial Research Data Services University of Alberta Edmonton Alberta Canada.

Zaeem A Siddiqi (ZA)

Division of Neurology, Department of Medicine, Faculty of Medicine and Dentistry University of Alberta Edmonton Alberta Canada.

Richard A Coulden (RA)

Department of Radiology and Diagnostic Imaging University of Alberta Hospital Edmonton Alberta Canada.

Richard Thompson (R)

Division of Cardiology University of Alberta Edmonton Alberta Canada.
Department of Medicine, Faculty of Medicine and Dentistry Mazankowski Alberta Heart Institute, University of Alberta Edmonton Alberta Canada.

James A White (JA)

Department of Cardiac Sciences University of Alberta Edmonton Alberta Canada.
Libin Cardiovascular Institute of Alberta, University of Calgary Calgary Alberta Canada.

Gavin Y Oudit (GY)

Division of Cardiology University of Alberta Edmonton Alberta Canada.
Department of Medicine, Faculty of Medicine and Dentistry Mazankowski Alberta Heart Institute, University of Alberta Edmonton Alberta Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH